BillionToOne is a molecular diagnostics company built around its patented single molecule next-generation sequencing (smNGS) platform and Quantitative Counting Templates (QCTs). The company uses this technology to detect and precisely quantify sparse genetic signals in cell-free DNA from a simple blood draw, with products focused on prenatal testing and oncology applications. Its commercial model combines laboratory testing, physician adoption, payor reimbursement, and clinical support services, rather than selling instruments or reagents. The company was founded in 2016, began receiving commercial samples in 2019, and has scaled rapidly while still operating as a relatively young diagnostics business. Management emphasizes AI-enhanced workflows, expanding clinical data repositories, and continued product development to strengthen its technical edge and broaden adoption.
7,5 %
68,3 %
2,4 %
+100,0 %
11.69
11.32
| % | |
|---|---|
| Prenatal diagnostics | 80% Blood-based prenatal tests, including UNITY and related screening products used to assess fetal and carrier risk. |
| Oncology diagnostics | 15% Liquid biopsy and other molecular oncology tests that detect and quantify cancer-related genetic signals. |
| Clinical trial and partnership services | 5% Testing and support services provided under strategic collaborations, including companion diagnostic work. |
BillionToOne sells primarily to obstetricians, genetic counselors, maternal-fetal medicine specialists, and other...
OB-GYNs, GCs, and MFMs buy UNITY and related prenatal tests to assess fetal and carrier risk early in pregnancy and to improve patient counseling.
Commercial and other payors influence whether tests are covered and at what rate, which directly affects adoption and realized revenue.
Strategic partners buy testing services for clinical trial support and companion diagnostic development.
Distributors send samples to U.S. labs in smaller international markets where patients often pay out of pocket.
The company is headquartered in the United States and generates the vast majority of its revenue domestically...
BillionToOne’s strategy is to deepen its competitive moat by expanding clinical data repositories and improving AI...
Prenatal testing is the core revenue engine, and broader physician and clinic adoption drives volume growth.
Coverage decisions determine whether tests are paid for and materially affect demand and realized pricing.
A larger data moat and better models can improve clinical utility and defend against competitors.
New end markets diversify the business beyond prenatal diagnostics and create additional growth vectors.
The company operates in a highly competitive molecular diagnostics market where established players can launch...
A large share of revenue depends on insurance coverage, claim approval, and reimbursement rates, which can change with policy and medical necessity decisions.
The company was founded in 2016 and has scaled quickly, making it harder to predict future execution, hiring needs, and operating leverage.
Large diagnostics companies and direct competitors can launch similar NIPT and carrier screening products, increasing pricing and adoption pressure.
The platform relies on patented QCT and smNGS technology, so adverse IP outcomes could reduce differentiation and protectability.
The company processes PHI and financial data across on-site and cloud systems, creating exposure to breaches, misuse, or service disruption.
MYGN · In Vitro & In Vivo Diagnostic Substances
Myriad Genetics develops and commercializes molecular diagnostic tests that help clinicians assess disease risk, guide treatment selection, and support earlier…
BOLD · Pharmaceutical Preparations
FLGT · Services-Medical Laboratories
GH · Services-Medical Laboratories
Guardant Health is a precision oncology company built around blood- and tissue-based cancer tests, real-world data, and AI analytics.
ONC · Pharmaceutical Preparations
NEO · Services-Testing Laboratories
NeoGenomics is a U.S.-based cancer diagnostics company that provides oncology testing and consultative pathology services to help clinicians identify, classify, and monitor cancer.
: 11/08/2026